130 results on '"Garcia vargas, J."'
Search Results
2. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
3. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma
4. Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel in the phase 3 ALSYMPCA trial: ID 039
5. Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial: ID 047
6. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
7. Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
8. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
9. 260P A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
10. Vorinostat in Combination with Other Anti-MM Agents: B257
11. Vorinostat plus Bortezomib in MM: A Phase I Study: A248
12. Vorinostat and Bortezomib in Relapsed/Refractory MM: A242
13. RALTITREXED (ʼTOMUDEXʼ) AND OXALIPLATIN (TOMOX) PRELIMINARY RESULTS OF A PHASE II STUDY OF CHEMORADIATION WITH PRE-OPERATIVE TREATMENT OF STAGE II/III RESECTABLE RECTAL CANCER: 603
14. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma
15. A phase II study of tomudex (T) in combination with epirubicin (E) and cisplatin (C) in patients with advanced oesophageal and gastric (OG) adenocarcinoma.
16. Influence des impuretés issues de la combustion du biodiesel sur les propriétés d’adsorption des catalyseurs d’oxydation: étude par DRIFT
17. SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS-1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA
18. COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA
19. EFFICACY AND SAFETY IN HIGH-RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB
20. Preparación de catalizadores Diesel NOx Trap por via coloidal
21. Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma
22. Highly active and stable Ru/K-OMS-2 for NO oxidation
23. Pd/Rh catalysts for the abatement of car emissions pollutants
24. Fe zeolite supported catalysts for the SCR-NH3 reaction
25. Influence du procédé de préparation et de support utilisé sur l'activité de catalyseurs du Fe-zéolites pour la NH3-SCR de NOx
26. Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma
27. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study
28. INTEGRATED SAFETY DATA WITH COPANLISIB MONOTHERAPY FROM PHASE I AND II TRIALS IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA
29. COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1)
30. Influence of the preparation method on the activity of Fe/ZMS-5 catalysts for the SCR of NOx with NH3
31. Re-treatment of Radium-223 From an International, Multicenter, Prospective, Single-Arm Trial in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
32. Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases
33. External-beam radiation therapy (EBRT) use and safety with Radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
34. External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
35. ChemInform Abstract: Silicon Carbide as Catalytic Support for Energy and Environmental Applications
36. EXTERNAL-BEAM RADIATION THERAPY (EBRT) USE AND SAFETY WITH RADIUM-223 DICHLORIDE (RA) IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES (METS) FROM THE ALSYMPCATRIAL
37. Long-term safety and real world clinical experience of radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the phase 3 ALSYMPCA study
38. 1000PD - Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study
39. 1001PD - Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma
40. ChemInform Abstract: Silicon Carbide as Catalytic Support for Energy and Environmental Applications
41. 865 Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial
42. Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
43. Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases : baseline prognostic factor subgroup analysis
44. Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases : A phase III randomized trial (ALSYMPCA)
45. 752P - Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases
46. Radium-223 Dichloride (Ra-223) Impact on Skeletal-Related Events, External Beam Radiation Therapy (EBRT), and Pain in Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases: Updated Results From the Phase 3 ALSYMPCA Trial
47. 101 Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) and bone metastases
48. Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase III Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases
49. 130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)
50. Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.